{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:03:10Z","timestamp":1771844590241,"version":"3.50.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the net benefit of biological agents (BA) used in JIA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We systematically searched databases up to March 2019 for randomized controlled trials (RCT) performed in JIA disease. Separate random-effects meta-analyses were conducted for efficacy (ACR paediatric score 30%, ACRpedi30) and serious adverse events for safety. In order to standardize the baseline risk, we performed a meta-analysis of baseline risk in the control group (for both efficacy and safety meta-analysis). The net benefit was determined as the risk difference of efficacy subtracted by the risk difference of safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 19 trials: 11 parallel RCTs (754 patients) and 8 withdrawal RCTs (704 patients). The net benefit ranged from 2.4% (adalimumab) to 17.6% (etanercept), and from 2.4% (etanercept) to 36.7%, (abatacept) in parallel and withdrawal trials assessing non-systemic JIA, respectively. In the systemic JIA category, the net benefit ranged from 22.8% (rilonacept) to 70.3% (canakinumab), and from 32.3% (canakinumab) to 58.2% (tocilizumab) in parallel and withdrawal trials, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The results suggest that a greater number of patients experienced therapeutic success without serious adverse events in the systemic onset JIA category compared with the BAs for non-systemic JIA categories. Baseline risk, design of trial and JIA categories impact the measure of net benefit of BAs in JIA patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa170","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T12:17:51Z","timestamp":1584447471000},"page":"2226-2236","source":"Crossref","is-referenced-by-count":7,"title":["The benefit\u2013risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9555-8645","authenticated-orcid":false,"given":"Natalia","family":"Cabrera","sequence":"first","affiliation":[{"name":"Laboratoire de Biom\u00e9trie et Biologie \u00c9volutive (UMR - CNRS 5558), University of Lyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Avila-Pedretti","sequence":"additional","affiliation":[{"name":"Department of Research, Universidad Nacional de Asuncion, San Lorenzo, Paraguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Belot","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, National Referral Centre for Rare Juvenile Rheumatological and Autoimmune Diseases (RAISE), Lyon University Hospital, University of Lyon, Lyon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Larbre","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospices Civils de Lyon, Lyon University Hospital, University of Lyon, Pierre-B\u00e9nite"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Mainbourg","sequence":"additional","affiliation":[{"name":"Laboratoire de Biom\u00e9trie et Biologie \u00c9volutive (UMR - CNRS 5558), University of Lyon, Lyon, France"},{"name":"Department of Internal and Vascular Medicine, National Referral Centre for Rare Juvenile Rheumatological and Autoimmune Diseases (RAISE), Hospices Civils de Lyon, University of Lyon, Pierre-B\u00e9nite"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Duquesne","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, National Referral Centre for Rare Juvenile Rheumatological and Autoimmune Diseases (RAISE), Lyon University Hospital, University of Lyon, Lyon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perrine","family":"Janiaud","sequence":"additional","affiliation":[{"name":"Laboratoire de Biom\u00e9trie et Biologie \u00c9volutive (UMR - CNRS 5558), University of Lyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behrouz","family":"Kassai","sequence":"additional","affiliation":[{"name":"Laboratoire de Biom\u00e9trie et Biologie \u00c9volutive (UMR - CNRS 5558), University of Lyon, Lyon, France"},{"name":"Department of Pharmaco-toxicology, Clinical Investigation Centre 1407 - INSERM, Hospices Civils de Lyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Cucherat","sequence":"additional","affiliation":[{"name":"Laboratoire de Biom\u00e9trie et Biologie \u00c9volutive (UMR - CNRS 5558), University of Lyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Lega","sequence":"additional","affiliation":[{"name":"Laboratoire de Biom\u00e9trie et Biologie \u00c9volutive (UMR - CNRS 5558), University of Lyon, Lyon, France"},{"name":"Department of Internal and Vascular Medicine, National Referral Centre for Rare Juvenile Rheumatological and Autoimmune Diseases (RAISE), Hospices Civils de Lyon, University of Lyon, Pierre-B\u00e9nite"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"2020082700372034900_keaa170-B1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jval.2014.11.001","article-title":"A unified framework for classification of methods for benefit-risk assessment","volume":"18","author":"Najafzadeh","year":"2015","journal-title":"Value Health"},{"key":"2020082700372034900_keaa170-B2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jclinepi.2009.07.002","article-title":"A first step to assess harm and benefit in clinical trials in one scale","volume":"63","author":"Boers","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2020082700372034900_keaa170-B3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2020082700372034900_keaa170-B4","article-title":"Optimisation of disease assessments in juvenile idiopathic arthritis","volume":"32","author":"Consolaro","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2020082700372034900_keaa170-B5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40272-017-0244-2","article-title":"Clinical trial design in juvenile idiopathic arthritis","volume":"19","author":"Balevic","year":"2017","journal-title":"Paediatr Drugs"},{"key":"2020082700372034900_keaa170-B6","doi-asserted-by":"crossref","first-page":"e41174","DOI":"10.1371\/journal.pone.0041174","article-title":"Challenges in coding adverse events in clinical trials: a systematic review","volume":"7","author":"Schroll","year":"2012","journal-title":"PLoS One"},{"key":"2020082700372034900_keaa170-B7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/pds.3982","article-title":"Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal","volume":"25","author":"Cr\u00e9pin","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020082700372034900_keaa170-B8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions (Cochrane book series)","author":"Higgins","year":"2008"},{"key":"2020082700372034900_keaa170-B9","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2020082700372034900_keaa170-B10","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2020082700372034900_keaa170-B11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat Med"},{"key":"2020082700372034900_keaa170-B12","doi-asserted-by":"crossref","first-page":"e010983","DOI":"10.1136\/bmjopen-2015-010983","article-title":"Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study","volume":"6","author":"Cheng","year":"2016","journal-title":"BMJ Open"},{"key":"2020082700372034900_keaa170-B13","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2020082700372034900_keaa170-B14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"2020082700372034900_keaa170-B15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2020082700372034900_keaa170-B16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1546-0096-8-24","article-title":"The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial","volume":"8","author":"Visvanathan","year":"2010","journal-title":"Pediatr Rheumatol Online J"},{"key":"2020082700372034900_keaa170-B17","author":"Zeng"},{"key":"2020082700372034900_keaa170-B18","author":"Zeng H, Ping"},{"key":"2020082700372034900_keaa170-B19","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"2020082700372034900_keaa170-B20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2020082700372034900_keaa170-B21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"2020082700372034900_keaa170-B22","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2020082700372034900_keaa170-B23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"2020082700372034900_keaa170-B24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"2020082700372034900_keaa170-B25","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"2020082700372034900_keaa170-B26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin Rheumatol"},{"key":"2020082700372034900_keaa170-B27","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2020082700372034900_keaa170-B28","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2020082700372034900_keaa170-B29","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"2020082700372034900_keaa170-B30","doi-asserted-by":"crossref","first-page":"R230","DOI":"10.1186\/ar4072","article-title":"Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement","volume":"14","author":"Horneff","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2020082700372034900_keaa170-B31","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"2020082700372034900_keaa170-B32","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020082700372034900_keaa170-B33","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2020082700372034900_keaa170-B34","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2020082700372034900_keaa170-B35","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020082700372034900_keaa170-B36","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/acr.22657","article-title":"A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis","volume":"67","author":"Burgos-Vargas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2020082700372034900_keaa170-B37","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.39145","article-title":"Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study","volume":"67","author":"Horneff","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2020082700372034900_keaa170-B38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12969-017-0138-4","article-title":"A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study","volume":"15","author":"Hissink Muller","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"2020082700372034900_keaa170-B39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/acr.23590","article-title":"A novel method to combine assessment of benefit and harm: outcome measures in rheumatology 3\u2009\u00d7\u20093 methodology applied to two active comparator trials","volume":"71","author":"Boers","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2020082700372034900_keaa170-B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2017-211108","article-title":"Learning the hard way: clinical trials in juvenile idiopathic arthritis","volume":"77","author":"Berard","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020082700372034900_keaa170-B41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.semarthrit.2016.07.001","article-title":"Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials","volume":"46","author":"Amarilyo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2020082700372034900_keaa170-B42","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","article-title":"Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials","volume":"55","author":"Tarp","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2020082700372034900_keaa170-B43","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2012-201991","article-title":"Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons","volume":"72","author":"Otten","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2020082700372034900_keaa170-B44","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jbspin.2018.08.003","article-title":"Safety of biological agents in paediatric rheumatic diseases: a real-life multicenter retrospective study using the JIRcohorte database","volume":"86","author":"Cabrera","year":"2019","journal-title":"Joint Bone Spine"},{"key":"2020082700372034900_keaa170-B45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12305","article-title":"Clinical trials in children","volume":"79","author":"Joseph","year":"2015","journal-title":"Br J Clin Pharmacol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/9\/2226\/33686297\/keaa170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/9\/2226\/33686297\/keaa170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T04:37:47Z","timestamp":1598503067000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/9\/2226\/5843846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,5,25]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa170","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,5,25]]}}}